Mol Med Rep:二球悬铃木花粉产生的Pla a 2过敏原的表达、纯化和表型分析

2017-11-17 AlexYang MedSci原创

悬铃木是户外人类过敏原的主要来源之一,并且能够诱导人类过敏性哮喘、鼻炎、接触性皮肤炎和其他过敏性疾病。Pla a 2是一种聚半乳糖醛酸酶并且在鉴定过的悬铃木木花粉中代表了主要过敏原。最近,有研究人员对Pla a 2进行了表达和春花,并且预测了Pla a 2的B和T细胞表型。研究人员将编码Pla a 2的基因克隆到了Pet28a载体中,随后转化到了DE3大肠杆菌细胞中,并将纯化过的Pla a 2进行

悬铃木是户外人类过敏原的主要来源之一,并且能够诱导人类过敏性哮喘、鼻炎、接触性皮肤炎和其他过敏性疾病。Pla a 2是一种聚半乳糖醛酸酶并且在鉴定过的悬铃木木花粉中代表了主要过敏原。最近,有研究人员对Pla a 2进行了表达和春花,并且预测了Pla a 2的B和T细胞表型。

研究人员将编码Pla a 2的基因克隆到了Pet28a载体中,随后转化到了DE3大肠杆菌细胞中,并将纯化过的Pla a 2进行蛋白免疫印迹分析。研究发现,在对悬铃木花粉过敏的病人的血清中,Pla a 2过敏原具有结合免疫球蛋白E的能力。另外,研究人员还利用DNAStar、生物信息学预测抗原肽和BepiPred1.0软件对Pla a 2的B细胞表型进行了预测;并利用NetMHCIIpan-3.0和-2.2对T细胞表型进行了预测。在他们的研究中,总共预测出了8种B细胞表型(15 24, 60 66, 78 86, 109 124, 232 240, 260 269, 298 306和315 322)和5种T细胞表型(62 67, 86 91, 125 132, 217 222 and 343 350)。最后,研究人员指出,这些发现也许能够用来改善过敏原免疫治疗效果,并且减少花粉相关的过敏性反应。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1396412, encodeId=8aca1396412fb, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442615, encodeId=359d14426151d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535157, encodeId=45a5153515e9c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608262, encodeId=2a77160826255, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262089, encodeId=8da7262089b7, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Nov 17 22:34:32 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1396412, encodeId=8aca1396412fb, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442615, encodeId=359d14426151d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535157, encodeId=45a5153515e9c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608262, encodeId=2a77160826255, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262089, encodeId=8da7262089b7, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Nov 17 22:34:32 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1396412, encodeId=8aca1396412fb, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442615, encodeId=359d14426151d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535157, encodeId=45a5153515e9c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608262, encodeId=2a77160826255, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262089, encodeId=8da7262089b7, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Nov 17 22:34:32 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-19 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=1396412, encodeId=8aca1396412fb, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442615, encodeId=359d14426151d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535157, encodeId=45a5153515e9c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608262, encodeId=2a77160826255, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262089, encodeId=8da7262089b7, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Nov 17 22:34:32 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-19 一叶知秋
  5. [GetPortalCommentsPageByObjectIdResponse(id=1396412, encodeId=8aca1396412fb, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442615, encodeId=359d14426151d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535157, encodeId=45a5153515e9c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608262, encodeId=2a77160826255, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 19 10:58:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262089, encodeId=8da7262089b7, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Nov 17 22:34:32 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-17 清风拂面

    谢谢分享.学习了

    0

相关资讯

患方索赔66万,肌注也要小心!

事件经过:7月底,河南患者,男,22岁,早起7点多来到当地一家村卫生室就诊。主诉:肚子疼,发热,且症状已经有几日。医生经过诊断后,给予药物治疗 :肌注了一针氨基比林(一支)和肌注了一针丁胺卡那和地米(各一支),并嘱咐其不缓解就去医院检查。当日,患者打针后出去玩了一上午,下午在家也没事,结果晚上7点钟不知道什么情况病情发生了改变,经120抢救无效死亡。

Sleep Med:中国儿童的睡眠障碍和过敏性疾病

良好的睡眠对儿童的生长、发育和免疫功能非常重要。最近,有研究人员在中国儿童中,进行了旨在探索是否睡眠障碍与过敏性疾病风险相关。研究包括了566名儿童(年龄23.9±0.7个月;51.1%为男孩),地点在中国上海。研究人员利用扩展版的简明婴儿睡眠调查问卷(BISQ-扩展版)对睡眠参数(总睡眠时间、入眠时间、夜间觉醒和打鼾)进行了评估,并利用标准调查问卷搜集了去年的4种过敏性疾病的信息(喘息、湿疹、食

Lancet Child&Adolescent Health:联合益生菌和花生口服免疫疗法的长期的临床和免疫效益

花生是常见的食物过敏原,是食物过敏中导致死亡人数最高的一种。花生过敏的症状有血压降低、面部和喉部肿胀,严重时阻碍呼吸,从而导致休克。近日,Lancet子刊上发表一篇对花生脱敏治疗的相关文章。

Nat Commun:研究人员有望开发出彻底根除过敏性疾病的新药!

【通过沉默免疫细胞对抗过敏】昆士兰大学的研究人员距离开发用于治疗炎症性疾病的新药更近了一步,这些疾病包括鼻炎,瘙痒,哮喘,湿疹和皮炎等过敏症。

NPJ Vaccines:重磅!可以根治牛皮癣的疫苗已经进入人体试验阶段

邓迪大学和牛津大学的研究表明,如何结合破伤风疫苗的病毒粒子治疗牛皮癣和过敏,甚至还可能预防阿尔茨海默氏症。

2017 EAACI免疫治疗指南:过敏的预防

2017年9月,欧洲变应性反应与临床免疫学会(EAACI)发布了过敏的预防指南。过敏性疾病是最常见的慢性疾病,包括过敏性湿疹/皮亚波,哮喘,过敏性鼻炎变应性鼻结膜炎,食物过敏和毒液过敏。本文主要诊断这些过敏性疾病的预防提出指导意见。